MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2662-2673

  Zhong, Haihong ^a   Fazenbaker, Christine ^a   Breen, Shannon ^a   Chen, Cui ^a   Huang, Jiaqi ^a   Morehouse, Christopher ^a   Yao, Yihong ^a   Hollingsworth, Robert E ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2014; CASPASE 3; CASPASE 7; DUSIGITUMAB; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 1A; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIGAND; MEDI-573; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; NEUTRALIZING ANTIBODY; SOMATOMEDIN; TARGET OF RAPAMYCIN KINASE; VISTUSERTIB;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA CONTENT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; RANDOMIZATION; SARCOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LIGANDS; MICE; MICE, NUDE; MORPHOLINES; PHOSPHORYLATION; RANDOM ALLOCATION; SARCOMA; SIGNAL TRANSDUCTION; SIROLIMUS; SOMATOMEDINS; TOR SERINE-THREONINE KINASES;

EID: 84919346723     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0144     Document Type: Article

References (42)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway- therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007;4:591-602.
3. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24.
4. Cinitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-70.
5. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
6. Baserga R. The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res 2009;315:727-32.
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
8. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Onclologist 2008;13:16-24.
9. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
10. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-target therapy. Curr Opin Investig Drugs 2009;10;1032-40.
11. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7.
12. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther targets 2008;12:589-603.
13. Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcomas. Clin Epidemiol 2013;5:147-162.
14. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-31.
15. Kim SY, Wan X, Helman LJ. Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull Cancer 2009;96:52-60.
16. Nationwide Children's Hospital. Pediatric preclinical testing program: Affymax database. Available from: http://pptp.nchresearch.org/
17. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
18. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54:2803-7.
19. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445-8.
20. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97.
21. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, et al. R1507, A fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010;55:67-75.
22. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The IGF-1 receptor targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71.
23. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-7.
24. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric testing program. Pediatr Blood Cancer 2010;54:921-6.
25. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, et al. Efficacy of Ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharm Exp Ther 2011;337:644-54.
26. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40.
27. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
28. Bjornsti M, Houghton PJ. The TOR pathway: a target for cancer therapy. Nature Rev 2004;4:335-48.
29. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. The Oncologist 2007;12:1007-18.
30. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
31. Guichard SM, Howard Z, Heathcote D, Roth M, Hughes G, Curwen J, et al. AZD2014, a dualmTORC1 andmTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 917.
32. Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, et al. Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 2011;6:e26177.
33. Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S. Identi fication of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's Sarcoma. Mol Endocrinol 2012;26:1603-1616.
34. Zhang L, Zhou W, Velculescu VE, Kern SC, Hruban RH, Hamilton SR, et al. Gene expression pro files in normal and cancer cells. Science 1997;276:1268-1272.
35. Belfiore A, Frasca F. IGFand insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:381-406.
36. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. PNAS 2010;107:10791-98.
37. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini P, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30:2730-2740.
38. Shin DH, Min HY, EL-Naggar AK, Lippman SM, Glisson B, Lee HY. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther 2011;10:2437-48
39. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012;18:2625-31.
40. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69:161-70.
41. Martines AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008;68:6260-70.
42. McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res 2013;19:4282-9.